Future/Novel Uses of Beta Blockers in Clinical Therapeutics

March 1986
Angiology;Mar1986 Part 2, Vol. 37 Issue 3, p218
Academic Journal
No abstract available.


Related Articles

  • atenolol.  // Davis's Drug Guide for Nurses, 9th edition;2005, p91 

    Presents clinical information on the beta blocker atenolol. Clinical indications for use; Therapeutic effects of the drug; Adverse reactions and side effects of the drug.

  • Self-poisoning with beta-blockers.  // British Medical Journal;4/22/1978, Vol. 1 Issue 6119, p1010 

    Focuses on the incidence of self poisoning with beta-blockers. Clinical features; Effects of the pharmacological properties on the therapeutic actions of beta blockers; Management of self-poisoning.

  • Beta-Blockers May Help With Breast Cancer Treatment.  // Heart Advisor;Apr2012, Vol. 15 Issue 4, p6 

    The article discusses the therapeutic uses of beta-blockers in breast cancer. It cites two studies, which indicate that beta-blockers may reduce the cardiovascular side effects of chemotherapy and prevent tumors from spreading. It also mentions the common beta-blockers, as well as several...

  • Preventing arrhythmias.  // Cortlandt Forum;4/25/2005, Vol. 18 Issue 4, p22 

    Evaluates the antiarrhythmic effect of beta blocker carvedilol. Pathology of arrhythmias; Therapeutics; Assessment of the efficacy of the beta blocker against arrhythmia.

  • Drug interactions and beta blockers. Beeley, Linda // British Medical Journal (Clinical Research Edition);11/17/1984, Vol. 289 Issue 6455, p1330 

    Determines the clinical importance of drug interactions and beta blockers in Great Britain. Identification of the pharmacokinetic interactions; Characterization of the beta blockers; Significance of pharmacodynamic interactions with beta blockers.

  • MERLIN Study Should Expand Ranexa In Angina, But Not ACS. Lorenzo, Aaron // BioWorld Today;3/8/2007, Vol. 18 Issue 46, p1 

    The article discusses the results of a clinical study on the angina drug Ranexa manufactured by CV Therapeutics Inc. Ranexa was first approved for second-line use in combination with the calcium channel blocker amlodopine, beta-blockers or nitrates. John Bluth of CV Therapeutics believes that...

  • F. Clinical Renal Pharmacology and Therapeutics.  // Kidney;Mar/Apr2003, Vol. 12 Issue 2, p92 

    Presents the results of several studies on clinical renal pharmacology and therapeutics. Analysis of the antihypersensitive efficacy and safety of darusentan; Assessment of the effects of aspirin and beta-blocker use in patients with chronic kidney disease; Relationship between the number of...

  • Beta-Blocker Therapy in Noncardiac Surgery. Poldermans, Don; Boersma, Eric // New England Journal of Medicine;7/28/2005, Vol. 353 Issue 4, p412 

    Comments on the use of beta-blockers in noncardiac surgery. Risk for death from myocardial infarction among patients receiving noncardiac surgery in the U.S.; Use of beta-blockers to regulate oxygen use in the heart following surgery; Need for clinical trials on the benefits of beta-blockers;...

  • Intravenous ... blockade in acute myocardial infarction. Owen, A. // BMJ: British Medical Journal (International Edition);07/25/98, Vol. 317 Issue 7153, p226 

    Editorial. Discusses the use of beta blockers in patients with myocardinal infraction. Information on the ISIS-4 clinical trial on intravenous beta blockade; Why beta blockade is infrequently used in Great Britain.

  • Beta blockers in chronic heart failure. Churchouse, Wendy // Practice Nurse;4/24/2009, Vol. 37 Issue 8, p43 

    The article discusses beta blockers and their use in the treatment of heart failure. The studies indicate that beta blockers are effective in managing heart failure and can be safely titrated to a therapeutic dose in the community setting. The three beta blockers that are licensed in Great...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics